Abstract 2354P
Background
EMT is a process through which epithelial cells acquire mesenchymal-like traits, such as increased migratory capacity, which facilitate cancer cell metastasis. Here we propose an interpretable, scalable, machine learning (ML)-based method to assess EMT status directly from H&E-stained images. We extracted human interpretable features (HIFs) quantifying cancer cell nuclear morphology and the tumor microenvironment from breast cancer H&E images and confirmed concordance with a known ground-truth EMT expression signature.
Methods
Using a breast cancer-specific EMT signature gene set, we calculated quantile normalized EMT scores for each patient in TCGA-BRCA with RNA-seq data (n = 751). Convolutional neural network models trained using H&E-stained whole slide images were used to extract a set of HIFs across available slides (n = 775). An ordinary least squares regression was run for each HIF against EMT score with tumor purity as a covariate. FDR correction was applied to all p-values.
Results
Lower EMT scores were associated with epithelial attributes, such as high nuclei circularity, while high EMT scores were associated with mesenchymal attributes, such as high nuclei eccentricity and greater variation in nuclei perimeter. Epithelial-type tumors were associated with increased immature stromal content and cancer cell proportion. Mesenchymal-type tumors were associated with increased mature stromal content and stromal cell proportion. Table: 2354P
HIF | Coefficient | Standard error | p-value | R2 | FDR corrected p-value |
Mean cancer cell nuclei circularity | -0.047 | 0.0087 | 8.60E-08 | 0.65 | 2.80E-07 |
Mean cancer cell nuclei eccentricity | 0.042 | 0.0089 | 2.30E-06 | 0.65 | 5.80E-06 |
Standard deviation of cancer cell nuclei perimeter | 0.073 | 0.0089 | 1.20E-15 | 0.67 | 8.30E-15 |
Area proportion immature stroma over all stroma | -0.035 | 0.0083 | 2.50E-05 | 0.65 | 5.20E-05 |
Area proportion mature stroma over all stroma | 0.033 | 0.0082 | 8.40E-05 | 0.65 | 0.00016 |
Count proportion cancer cells over all cells | -0.12 | 0.0075 | 6.50E-51 | 0.75 | 9.80E-49 |
Count proportion stromal cells over all cells | 0.098 | 0.0078 | 1.20E-32 | 0.71 | 3.60E-31 |
Conclusions
ML model-generated HIFs effectively capture cancer cell morphology reflective of EMT status, including nuclei eccentricity and circularity. The relationships observed in these results are concordant with previous studies showing increased EMT in tumors with greater extracellular matrix stiffness and large numbers of cancer associated fibroblasts. Overall these results reflect significant agreement between EMT scores and HIFs, indicating potential for quantification of EMT states directly from H&E images.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
PathAI, Inc.
Funding
PathAI, Inc.
Disclosure
C. Kirkup, S. Vilchez, S. Srinivasan, M. Lin, J. Abel, M. Drage, J. Conway, A. Khosla, A. Taylor-Weiner: Financial Interests, Full or part-time Employment: PathAI, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
2222P - Frequent TERT gains in metastatic papillary thyroid carcinoma
Presenter: Sara Gil
Session: Poster session 16
2223P - Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer
Presenter: Sergi Clavé
Session: Poster session 16
2224P - Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry
Presenter: Maria Victoria San Roman Gil
Session: Poster session 16
2225P - FOX1 (rs965513), NKX2-1 (rs944289) and BRAF (V600E) gene mutations and their role in development of papillary thyroid cancer
Presenter: Darko Katalinic
Session: Poster session 16
2226P - Survival benefit of radioiodine therapy (RAI) in papillary thyroid cancer variants (PTCV): A SEER analysis
Presenter: Sakhr Alshwayyat
Session: Poster session 16
2227P - The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: A single-arm phase II clinical trial
Presenter: Jianhong Yu
Session: Poster session 16
2228P - Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution
Presenter: Ryutaro Onaga
Session: Poster session 16
2229P - Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
Presenter: Lori Wirth
Session: Poster session 16
2323P - Multi-omic spatial phenotyping of the NSCLC tumour microenvironment for the development of a spatial score associated with immunotherapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 16
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Presenter: Ander Puyalto
Session: Poster session 16